| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
The primary target of this compound is the androgen receptor (AR), as it contains the 3-fluoro-4-(methylcarbamoyl)phenyl motif which serves as the core AR-binding element in nonsteroidal androgen receptor antagonists. The compound is structurally related to Enzalutamide, a well-known AR antagonist used in prostate cancer treatment, and is identified as Enzalutamide Impurity 52. The 3-fluoro-4-(methylcarbamoyl)phenyl group is critical for binding to the androgen receptor's ligand-binding domain, where it competes with endogenous androgens such as testosterone and dihydrotestosterone. By blocking AR signaling, compounds with this pharmacophore can inhibit androgen-dependent tumor growth. The compound may also interact with other targets due to its structural features, but AR is the primary known target.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro studies on this compound are limited as it is primarily characterized as an impurity standard for Enzalutamide rather than a therapeutic agent. However, related compounds containing the 3-fluoro-4-(methylcarbamoyl)phenyl motif have demonstrated potent androgen receptor antagonism in cell-based assays. Standard in vitro assays include AR binding studies using radiolabeled ligands, reporter gene assays measuring AR transcriptional activity, and proliferation assays using androgen-dependent prostate cancer cell lines such as LNCaP or VCaP. The compound may also be evaluated for its effects on AR signaling pathways, including downstream gene expression and protein phosphorylation. Its role as an impurity standard means it is used primarily in analytical method development and quality control. |
| ln Vivo |
In vivo studies on this compound are limited as it is primarily characterized as an impurity standard for Enzalutamide rather than a therapeutic agent. Related compounds containing the 3-fluoro-4-(methylcarbamoyl)phenyl motif have been evaluated in xenograft models of prostate cancer, where they demonstrate inhibition of tumor growth through AR antagonism. Standard in vivo protocols involve administration via oral gavage in athymic nude mice bearing androgen-dependent tumor xenografts, with monitoring of tumor volume, body weight, and survival. The compound's role as an impurity standard means it is used primarily in analytical method development and quality control rather than in pharmacological studies.
|
| Enzyme Assay |
Non-cell-based enzyme or receptor binding assays for this compound typically involve competitive binding studies using purified androgen receptor protein. Standard protocols include incubating varying concentrations of the test compound with the AR ligand-binding domain and a radiolabeled androgen (e.g., [³H]-R1881 or [³H]-DHT) in appropriate buffer systems, followed by separation of bound from free ligand via filtration or charcoal adsorption. Binding affinity (Ki or IC₅₀ values) is calculated using nonlinear regression analysis. Surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) may also be employed to measure direct binding interactions. As an impurity standard, the compound is used in analytical method development and quality control applications for Enzalutamide.
|
| Cell Assay |
Cell-based assays for this compound typically utilize androgen receptor-positive prostate cancer cell lines such as LNCaP or VCaP. Standard protocols involve culturing cells in androgen-depleted media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.01-100 μM) for 24-72 hours. AR transcriptional activity is measured using luciferase reporter gene assays, while cell proliferation is assessed using MTT or CellTiter-Glo assays. The compound's effects on AR target gene expression (e.g., PSA, TMPRSS2) can be evaluated by qPCR. As an impurity standard, the compound is used primarily in analytical method development and quality control for Enzalutamide.
|
| Animal Protocol |
In vivo animal studies for this compound typically involve xenograft models of prostate cancer in athymic nude mice. Standard protocols include subcutaneous implantation of AR-positive prostate cancer cells (e.g., LNCaP or VCaP), followed by administration of the test compound via oral gavage at doses ranging from 1-50 mg/kg body weight. Tumor volume is measured twice weekly using calipers, and body weight is monitored for toxicity assessment. At study termination, tumors are collected for histopathological examination and biomarker analysis. As an impurity standard, the compound is used primarily in analytical method development and quality control rather than in pharmacological studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for this compound can be inferred from structurally related AR antagonists such as Enzalutamide. As a small molecule (molecular weight 282.31 g/mol) with moderate lipophilicity, it is expected to have reasonable oral bioavailability. The ethyl ester group is likely to be hydrolyzed in vivo to the corresponding carboxylic acid metabolite. The compound shows moderate solubility in organic solvents and can be formulated for in vitro and in vivo studies. For in vivo administration, formulations using suitable co-solvent systems may be employed. The compound should be stored as powder at -20°C for long-term preservation. Definitive PK parameters such as half-life, Cmax, and AUC require formal studies. As an impurity standard, PK data may not be available.
|
| Toxicity/Toxicokinetics |
Toxicological data for this specific compound are limited as it is primarily used as an impurity standard for Enzalutamide rather than as a therapeutic agent. Related AR antagonists have been extensively studied and show manageable toxicity profiles, including fatigue, hypertension, and hepatotoxicity at therapeutic doses. Appropriate safety precautions should be observed during handling, including the use of personal protective equipment and work in well-ventilated areas. The compound may cause skin and eye irritation upon contact. Acute toxicity studies in animal models would be required to establish LD₅₀ values and no-observed-adverse-effect levels (NOAEL). For in vitro cytotoxicity assessment, the compound can be tested in mammalian cell lines using standard MTT or LDH release assays.
|
| References | |
| Additional Infomation |
Ethyl 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate is an alanine derivative and a known impurity (Impurity 52) of Enzalutamide, a nonsteroidal androgen receptor antagonist used in the treatment of prostate cancer. The 3-fluoro-4-(methylcarbamoyl)phenyl motif serves as the core AR-binding element in nonsteroidal androgen receptor antagonists. The compound is studied for its potential use in drug development, particularly in fields like cancer, inflammation, or metabolic diseases. As an impurity standard, it is supplied with detailed characterization data compliant with regulatory guidelines for analytical method development and quality control applications. It is not an approved drug and has not undergone clinical trials as a therapeutic agent; it is strictly for research purposes.
|
| Molecular Formula |
C14H19FN2O3
|
|---|---|
| Molecular Weight |
282.31
|
| Exact Mass |
282.138
|
| CAS # |
1258638-92-4
|
| PubChem CID |
56971687
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.586
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
20
|
| Complexity |
360
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(C(C)(NC1=CC(F)=C(C(NC)=O)C=C1)C)=O
|
| InChi Key |
GBQUYIPPBGFGPC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H19FN2O3/c1-5-20-13(19)14(2,3)17-9-6-7-10(11(15)8-9)12(18)16-4/h6-8,17H,5H2,1-4H3,(H,16,18)
|
| Chemical Name |
ethyl 2-[3-fluoro-4-(methylcarbamoyl)anilino]-2-methylpropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (354.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5422 mL | 17.7110 mL | 35.4221 mL | |
| 5 mM | 0.7084 mL | 3.5422 mL | 7.0844 mL | |
| 10 mM | 0.3542 mL | 1.7711 mL | 3.5422 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
